Leverage our technologies to identify and validate potential drug targets:
- Flow- and CyTOF-based immune profiling
- Organotypic spheroids
Our target identification efforts feed directly into our partners’ drug discovery efforts, fueling preclinical development pathways.
Screening assay identifies new immunotherapy targets
3D microfluidic device models tumor microenvironment